ELDN
Eledon
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
ELDN Profile
Eledon Pharmaceuticals, Inc.
A clinical stage biotech company that develops treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS
19900 MacArthur Boulevard, Suite 550, Irvine, California 92612
--
Eledon Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on March 26, 2004. The company is a clinical-stage biopharmaceutical company focused on developing life-changing targeted drugs for people who require organ or cell-based transplantation, have autoimmune diseases, or have amyotrophic lateral sclerosis. The company's lead compound under development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target that they believe has broad therapeutic potential.